Agios Pharmaceuticals Stock News

– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July –

– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND ® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions –

Mitapivat got approved for PK deficiency. They have multiple label expansion potential.

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, tod

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Jackie Fouse – Chief Executive Officer Sarah Gheuens – Chief Medical Officer

– Received U.S. FDA Approval for PYRUKYND®, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios’ First Genetically Defined Disease Med

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, tod

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes –

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares, rose in value on Friday, 03/11/22, with the stock price down by -8.66% to the previous day’s close as strong demand from buyers drove the stock to $28.70. Actively observing the price movement in the last trading, the stock closed the session at $31.42, falling within a range of $28.65 … Looking For A Top Momentum Stock? Why Agios Pharmaceuticals Inc. (NASDAQ: AGIO) Is A Great Pick Read More »

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) price on Friday, March 04, fall -1.87% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $31.53. A look at the stock’s price movement, the close in the last trading session was $32.13, moving within a range at $31.375 and $32.70. The beta value … Agios Pharmaceuticals Inc.’s (AGIO) Stock Is Harder To Predict Than You Think Read More »

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG